Integrated safety of ixekizumab in patients with moderate to severe psoriasis: Results from a pooled analysis of 7 clinical trials - 21/04/16
Bruce Strober, MD, PhD, University of Connecticut School of Medicine, Farmington, CT, United States; Kim Papp, MD, PhD, Probity Medical Research, Waterloo, Ontario, Canada; Craig Leonardi, MD, Saint Louis University School of Medicine, St Louis, MO, United States; Robert Bissonnette, MD, Innovaderm Research, Montreal, Quebec, United States; Laura Ferris, MD, PhD, UPMC Department of Dermatology, Pittsburgh, PA, United States; Ulrich Mrowietz, MD, Universitatsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany; Carle Paul, MD, PhD, Department of Dermatology, Paul Sabatier University, Toulouse, France; Mark Lebwohl, MD, Icahn School of Medicine at Mount Sinai, New York, NY, United States; Daniel Braun, MD, Eli Lilly and Company, Indianapolis, IN, United States; Kristian Reich, MD, Dermatologikum Hamburg and Georg-August University, Gottingen, Germany
Le texte complet de cet article est disponible en PDF. Supported by Eli Lilly and Company. |
Vol 74 - N° 5S1
P. AB58 - mai 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?